###begin article-title 0
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Knocking-Down Cyclin A2 by siRNA Suppresses Apoptosis and Switches Differentiation Pathways in K562 Cells upon Administration with Doxorubicin
###end article-title 0
###begin p 1
Conceived and designed the experiments: JR XQ. Performed the experiments: XW. Analyzed the data: XW YS JR. Contributed reagents/materials/analysis tools: YS. Wrote the paper: XW JR XQ.
###end p 1
###begin p 2
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 165 166 165 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 397 398 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 574 575 574 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 664 665 664 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 815 816 815 816 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1040 1041 1040 1041 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1067 1068 1067 1068 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1247 1252 <span type="species:ncbi:9606">human</span>
Cyclin A2 is critical for the initiation of DNA replication, transcription and cell cycle regulation. Cumulative evidences indicate that the deregulation of cyclin A2 is tightly linked to the chromosomal instability, neoplastic transformation and tumor proliferation. Here we report that treatment of chronic myelogenous leukaemia K562 cells with doxorubicin results in an accumulation of cyclin A2 and follows by induction of apoptotic cell death. To investigate the potential preclinical relevance, K562 cells were transiently transfected with the siRNA targeting cyclin A2 by functionalized single wall carbon nanotubes. Knocking down the expression of cyclin A2 in K562 cells suppressed doxorubicin-induced growth arrest and cell apoptosis. Upon administration with doxorubicin, K562 cells with reduced cyclin A2 showed a significant decrease in erythroid differentiation, and a small fraction of cells were differentiated along megakaryocytic and monocyte-macrophage pathways. The results demonstrate the pro-apoptotic role of cyclin A2 and suggest that cyclin A2 is a key regulator of cell differentiation. To the best of our knowledge, this is the first report that knocking down expression of one gene switches differentiation pathways of human myeloid leukemia K562 cells.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 334 337 334 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Hartwell1">[1]</xref>
###xml 532 533 532 533 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 676 679 676 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Lehner1">[2]</xref>
###xml 680 683 680 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-SobczakThepot1">[5]</xref>
###xml 772 775 772 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Bui1">[6]</xref>
###xml 776 780 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Liao1">[15]</xref>
###xml 816 817 816 817 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 891 894 891 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Bui1">[6]</xref>
###xml 896 900 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Liao1">[15]</xref>
###xml 1059 1062 1059 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Volm1">[9]</xref>
###xml 1063 1067 1063 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Paterlini1">[14]</xref>
###xml 719 724 <span type="species:ncbi:9606">human</span>
Tumor cells are characterized by deregulation of cell cycle checkpoints, leading to uncontrolled cell division and proliferation under conditions where non-transformed cells cannot enter and pass through the cell cycle. All these may come from over-expression of cyclins and the abnormal activation of cyclin-dependent kinases (CDKs) [1]. Cyclins are a superfamily of proteins whose levels vary in a cyclical fashion during the cell cycle to activate specific CDK required for the proper progression through the cell cycle. Cyclin A2, which is essential for initiation and progression of DNA replication as well as for cell cycle progression through G1/S and G2/M transitions [2]-[5], is over-expressed in a variety of human cancers compared with normal cells and tissues [6]-[15]. Deregulated expression of cyclin A2 seems to be closely associated with early events in tumor transformation [6], [15]. In addition, its expression level in many types of cancers appears to be of prognostic value such as prediction of aggressiveness, survival or early relapse [9]-[14].
###end p 4
###begin p 5
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Malumbres1">[16]</xref>
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Ortega1">[17]</xref>
###xml 659 663 659 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Ortega1">[17]</xref>
###xml 698 699 698 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 766 770 766 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Murphy1">[18]</xref>
###xml 787 792 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 820 821 820 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 837 838 837 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 929 933 929 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Chen1">[19]</xref>
###xml 1061 1062 1061 1062 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1078 1079 1078 1079 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1144 1145 1144 1145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1266 1270 1266 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang1">[20]</xref>
###xml 1315 1316 1315 1316 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 525 530 <span type="species:ncbi:10090">mouse</span>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
###xml 1149 1154 <span type="species:ncbi:9606">human</span>
Until recently it has been held that CDK2, presumed master of the known CDK isoforms, is a promising anticancer target for developing small molecule inhibitors. The first-generation CDK inhibitors, flavopiridol and CY-202, are in late-stage clinical trials, and have only modest activity [16]. Recent findings [17], however, suggest that CDK2 may not be a key cell cycle player and question whether selective CDK2 inhibition is a useful cancer therapy strategy. No cell cycle abnormalities are observed in either a CDK2 null mouse or following acute ablation of CDK2 in primary cells, indicating that this gene is not strictly required for cell proliferation [17]. In contrast, deletion of cyclin A2 in knockout mice is associated with an embryonic lethal phenotype [18]. Moreover, Fine et al. demonstrated that cyclin A2 and/or cyclin A2- CDK2 complex but not CDK2 is a promising anticancer target with a high therapeutic index [19]. Therefore, inhibitors of CDK2 may not be appropriate for cancer therapy and more efforts are focused on inhibition of cyclin A2 and/or cyclin A2- CDK2 complex activity. We have shown that reduction of cyclin A2 in human chronic myelogenous leukaemia K562 cells using small interfering RNA significantly inhibits cell proliferation [20], further supporting the notion that cyclin A2 can serve as a novel therapeutic target.
###end p 5
###begin p 6
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Czyz1">[21]</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Zuryn1">[22]</xref>
###xml 416 420 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang2">[28]</xref>
###xml 486 487 486 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 605 609 605 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-HoriguchiYamada1">[29]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Rieber1">[33]</xref>
###xml 690 691 690 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Apoptosis and differentiation are the predominant two mechanisms by which chemotherapeutic agents kill tumor cells. Low dose of doxorubicin (DOX) induces erythroid differentiation in K562 cells, while high concentration of DOX promotes apoptosis [21]. Although many molecular pathways are involved in the apoptosis-regulatory mechanism, evidences suggest that the cell cycle and apoptosis may be interconnected [22]-[28]. Several studies have shown that increased expression of cyclin A2 is found in cells in response to several apoptotic stimuli, but very few studies have dealt with this issue directly [29]-[33]. So it is important to clarify whether the decreased expression of cyclin A2 is a cause of cell differentiation or a result of differentiation response.
###end p 6
###begin p 7
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Liu1">[34]</xref>
###xml 300 304 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Kam1">[36]</xref>
###xml 425 429 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Li2">[37]</xref>
###xml 488 492 488 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Li3">[38]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Peng1">[39]</xref>
###xml 671 675 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Zhao1">[40]</xref>
###xml 677 681 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Zhao2">[41]</xref>
###xml 741 742 741 742 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 907 908 907 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1175 1176 1175 1176 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1231 1232 1231 1232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1312 1313 1312 1313 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 450 455 <span type="species:ncbi:9606">human</span>
###xml 607 612 <span type="species:ncbi:9606">human</span>
Carbon nanotubes possess the unique features of being able to enter a living cell without causing its death or without inflicting other damage and can shuttle biological molecules into mammalian cells, indicating their potential application as a vector for the delivery of therapeutic molecules [34]-[36]. Recently we have reported that single wall carbon nanotubes (SWNTs) can induce a sequence-dependent B-A DNA transition [37], selectively induce human telomeric i-motif DNA formation [38], accelerate S1 nuclease cleavage rate [39], cause single-stranded poly(rA) to form a duplex structure and bind to human telomeric i-motif DNA under molecular-crowding conditions [40], [41]. Herein, we explore whether altering the levels of cyclin A2 in K562 cells using RNAi delivered by SWNTs can influence cell apoptosis and differentiation induced by chemotherapeutic agent DOX. K562 cells with reduced cyclin A2 showed a significant decrease in growth suppression, apoptosis and erythroid differentiation, and were differentiated along megakaryocytic and macrophage-monocytic pathways upon administration with DOX. These findings indicate a positive correlation between cyclin A2 and apoptosis induced by DOX and suggest that cyclin A2 is a key regulator of cell differentiation, supporting the notion that cyclin A2 is an important regulator for cell cycle as well as for cell apoptosis and differentiation. To the best of our knowledge, this is the first report that knocking down expression of one gene can switch K562 cells differentiation pathways.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Upregulation of cyclin A2 during apoptosis of K562 cells induced by DOX
###end title 9
###begin p 10
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Gewirtz1">[42]</xref>
###xml 207 213 207 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g001">Fig. 1</xref>
###xml 397 398 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 426 432 426 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g002">Fig. 2</xref>
###xml 442 443 442 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 585 586 585 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 748 749 748 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
DOX can inhibit growth of a variety of cancer cells [42]. To measure apoptosis rates induced by varying concentrations of DOX in K562 cells, we use acridine orange (AO)/ethidium bromide (EB) staining assay (Fig. 1). The percentage of apoptotic cells increased with time in a dose dependent fashion. RT-PCR and western blotting were used for studying the effect of DOX on the expression of cyclin A2 in K562 cells. As shown in Fig. 2, cyclin A2 expression levels increased with the increase of DOX, and a positive correlation was observed. These results show that expression of cyclin A2 was significantly up-regulated in DOX-treated K562 cells at time points when DOX caused a significant amount of apoptosis, indicating that the levels of cyclin A2 are correlated with the ability of DOX to induce apoptosis in K562 cells.
###end p 10
###begin title 11
Dose- and time-dependent apoptosis of K562 cells upon administration with DOX.
###end title 11
###begin p 12
Apoptotic cells were determined by AO/EB staining. Tests were done in triplicate, counting a minimum of 300 total cells from at least three random microscope fields each.
###end p 12
###begin title 13
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Expression of cyclin A2 in K562 cells administered with varying concentrations of DOX.
###end title 13
###begin p 14
RT-PCR (A) and western blotting (B) were performed 32 hours and 60 hours after drug administration, respectively.
###end p 14
###begin title 15
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Suppression of DOX-induced growth inhibition by down-regulation of cyclin A2 with siRNA delivered by SWNTs
###end title 15
###begin p 16
###xml 137 138 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 201 202 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang1">[20]</xref>
###xml 260 261 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 319 320 319 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 528 534 528 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g003">Fig. 3</xref>
###xml 642 643 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 965 966 961 962 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1016 1023 1012 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006665.s001">Fig. S1</xref>
###xml 1112 1113 1108 1109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1336 1343 1332 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006665.s002">Fig. S2</xref>
###xml 1358 1364 1354 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g004">Fig. 4</xref>
###xml 1368 1370 1364 1366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1454 1456 1446 1448 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1552 1553 1540 1541 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
We have previously demonstrated that functionalized single wall carbon nanotubes (SWNTs) can efficiently deliver siRNA targeting cyclin A2 into K562 cells, resulting in specific suppression of cyclin A2 expression [20]. Here, we use SWNTs to transfect cyclin A2 siRNA into K562 cells and evaluate the effect of cyclin A2 on growth inhibition induced by DOX. Two hours after transfection, DOX was added. Cell proliferation was examined by trypan blue exclusion method and methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. Fig. 3 showed cell growth curves of K562 cells after various treatments. It can be seen that depletion of cyclin A2 inhibited cell proliferation while carbon nanotubes vector had no apparent effect on growth inhibition as well as no additive or synergetic effect on cell toxicology of DOX. DOX (0.4 microM) significantly suppressed cell growth, nevertheless, much less growth inhibition was observed in cells incubated with both cyclin A2 siRNA and DOX, supported by microscopic results (Fig. S1). In order to further quantitively investigate the effect of down-regulation of cyclin A2 on the growth inhibition, MTT assays were carried out 24 h after incubation with DOX. Interaction of DOX with MTT was also checked in a cell free system and the results indicated that DOX showed no inference to MTT assay (Fig. S2). As shown in Fig. 4, IC50 of non-transfected cells was about 2.5 microM. For siRNA transfected K562 cells, IC50 was about 5.0 microM. The results clearly demonstrate that down-regulation of cellular cyclin A2 level suppress DOX-induced growth inhibition.
###end p 16
###begin title 17
###xml 51 52 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Growth curves of K562 cells in response to cyclin A2 siRNA delivered by SWNTs and DOX.
###end title 17
###begin p 18
The viable cells were counted by trypan blue exclusion at indicated time points. The data shown here represent the average of two independent experiments.
###end p 18
###begin title 19
###xml 31 32 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Effect of depletion of cyclin A2 on the survival of K562 cells treated with DOX.
###end title 19
###begin p 20
###xml 36 37 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 156 177 156 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
Cells were transfected with cyclin A2 siRNA (o) or not (*) two hours prior to the addition of drug. The viability was assessed by MTT assay as specified in Materials and Methods. The data shown here were means of two separate experiments performed in triplicate.
###end p 20
###begin title 21
###xml 78 79 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Suppression of DOX-induced apoptotic cell death by down-regulation of cyclin A2 with siRNA delivered by SWNTs
###end title 21
###begin p 22
###xml 31 32 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 108 109 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 180 181 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 287 293 283 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g005">Fig. 5</xref>
###xml 491 492 487 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 684 685 680 681 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 861 870 857 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006665.s003">Figure S3</xref>
###xml 914 915 910 911 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1058 1059 1054 1055 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
To investigate whether cyclin A2 participates in cell apoptosis death and determine if reduction of cyclin A2 has an effect on apoptosis induced by DOX, siRNA specific for cyclin A2 was transfected into K562 cells by SWNTs, and low dose of DOX (0.4 microM) was administered. As shown in Fig. 5, carbon nanotubes vector showed no apparent cell toxicology, while numerous larger cells and typical lobular nuclei were observed in cells incubated with DOX. For cells coadministered with cyclin A2 siRNA and DOX, much less apoptotic nuclei were observed, and the size of live cells was much bigger than that of the control cells. Statistics analysis showed that down-regulation of cyclin A2 significantly reduced the apoptosis rate from more than 60% to about 20%. Similar results were obtained by annexin V-PI double staining flow cytometric technique (as shown in Figure S3). These clearly indicated lowering cyclin A2 level in K562 cells led to suppression of apoptosis, thus a marked decrease in DOX susceptibility, which provide direct evidence that cyclin A2 is involved in cellular responses to apoptosis.
###end p 22
###begin title 23
Morphological observation of K562 cells with a fluorescence microscope.
###end title 23
###begin p 24
###xml 58 79 58 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 427 428 423 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cells were stained with AO/EB dye mixture as described in Materials and Methods section. Shown here were the representative images of three separate experiments. (A): upper left, untreated control cells; upper right, cells treated with transfection vector SWNTs for 32 h; lower left, cells were incubated with 0.4 microM DOX for 32 h, many cells appeared typical apoptotic bleb phenomenon; lower right, two hours after cyclin A2 siRNA transfection, cells were then administered with 0.4 microM DOX for additional 32 h. B: quantification of the live, apoptotic, and necrotic cells. Tests were done in triplicate, counting a minimum of 300 total cells each.
###end p 24
###begin title 25
###xml 52 53 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The cytoplasmic subcellular distribution of cyclin A2 correlates with apoptosis of K562 cells induced by DOX
###end title 25
###begin p 26
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 144 145 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Zuryn1">[22]</xref>
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Grzanka1">[23]</xref>
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Meikrantz2">[26]</xref>
###xml 259 260 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 366 367 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 395 402 395 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g006">Fig. 6A</xref>
###xml 562 563 562 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 636 643 636 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006665.s004">Fig. S4</xref>
###xml 694 695 694 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 777 784 777 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g006">Fig. 6B</xref>
###xml 795 796 795 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 871 878 871 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g006">Fig. 6C</xref>
###xml 933 934 933 934 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Early reports have demonstrated that there is a link between cyclin A2 subcellular localization and its cell function, and the level of cyclin A2 is correlated to cell apoptosis [22], [23], [26]. For clarifying whether the subcellular distribution of cyclin A2 in K562 cells correlates with apoptosis induced by DOX, indirect immunofluorescence detection of cyclin A2 was performed. As shown in Fig. 6A, a significant fraction of cells underwent apoptosis and orange nuclei were observed, where DOX was mostly located. The immunofluorescence labeling of cyclin A2 showed its presence predominantly in the nucleus of control K562 cells (Fig. S4), whereas in cells administered with DOX, cyclin A2 was mainly located at the cytoplasm of early and late phases of apoptotic cells (Fig. 6B). Cyclin A2 labeling was not found in the K562 cells incubated with non-immune serum (Fig. 6C). The results indicated that translocation of cyclin A2 from the nucleus to cytoplasm was connected with its role in apoptosis.
###end p 26
###begin title 27
###xml 41 42 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The sub-cellular distribution of cyclin A2 in K562 cells correlated with cell apoptosis.
###end title 27
###begin p 28
###xml 147 148 143 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 179 200 175 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 425 426 421 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cells were administered with 0.4 microM DOX for 32 h. A significant fraction of cells underwent apoptosis. Immunofluorescence detection of cyclin A2 was performed as described in Materials and Methods section. A: representative fluorescence microscopy image of K562 cells after treatment. Orange nuclei were observed, where DOX was mostly located; B: representative immunofluorescence microscopy image of K562 cells. Cyclin A2, normally located at nucleus, can be observed in cytoplasm of early and late phases of apoptotic cells. C: representative microscopy image of negative control immunofluorescence in K562 cells. No significant non-specific signal was observed.
###end p 28
###begin title 29
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Suppression of cyclin A2 by siRNA can switch differentiation pathways of K562 cells induced by DOX
###end title 29
###begin p 30
###xml 52 53 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 347 351 347 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Gewirtz1">[42]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Minotti1">[43]</xref>
###xml 471 478 471 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006665.s005">Fig. S5</xref>
###xml 738 739 738 739 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 895 901 895 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g007">Fig. 7</xref>
As mentioned above, cells treated with both cyclin A2 siRNA and DOX were much bigger than the control. Since enlarged phenotype may suggest cell differentiation, we performed the benzidine staining to assess erythroid differentiation, which was the differentiation pathway of K562 cells upon treatment with anthracycline antibiotics including DOX [42], [43]. Representative microscopy images of the benzidine staining in K562 cells after various treatments were shown in Fig. S5. For untreated cultures and cells administered with SWNTs, the percentages of benzidine positive cells were very low (less than 2%). Forty hours after incubation with DOX, around 14% benzidine positive cells were observed. However, down-regulation of cyclin A2 by siRNA in K562 cells substantially suppressed erythroid differentiation upon administration with DOX (less than 1% benzidine positive cells, as shown in Fig. 7).
###end p 30
###begin title 31
###xml 40 41 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Knocking-down the expression of cyclin A2 in K562 cells significantly inhibited erythroid differentiation induced by low concentration DOX.
###end title 31
###begin p 32
###xml 36 37 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 372 373 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 382 383 378 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Cells were transfected with cyclin A2 siRNA or not two hours prior to the addition of 0.4 microM DOX. Forty hours later, erythroid differentiation was scored by the benzidine staining method to determine the percentage of hemoglobin-positive K562 cells. Tests were done four times, counting a minimum of 300 total cells from at least three random microscope fields each. *p<0.05, **p<0.001 vs. control untreated cells by Student's t-test.
###end p 32
###begin p 33
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 395 402 395 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006665.s006">Fig. S6</xref>
###xml 471 472 471 472 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 573 574 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y</italic>
###xml 644 645 644 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">X</italic>
###xml 809 816 809 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006665.s007">Fig. S7</xref>
###xml 870 871 870 871 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 973 979 961 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g008">Fig. 8</xref>
###xml 1093 1100 1081 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006665.s008">Fig. S8</xref>
###xml 1312 1313 1288 1289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1329 1335 1305 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006665-g009">Fig. 9</xref>
###xml 1651 1655 1603 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Czyz1">[21]</xref>
###xml 1657 1661 1609 1613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Gewirtz1">[42]</xref>
###xml 1663 1667 1615 1619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Minotti1">[43]</xref>
###xml 1752 1753 1704 1705 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
To determine whether K562 cells with reduced cyclin A2 upon treatment with DOX underwent megakaryocytic pathway and monocyte-macrophage differentiation, which are the other two differentiation pathways of K562 cells, flow cytometric measurement of megakaryocytic specific surface antigen CD61 (GPIIIa) and nitro blue tetrazolium (NBT) reduction assay were carried out, respectively. As shown in Fig. S6, in comparison with the control, cells co-administered with cyclin A2 siRNA and DOX showed significant increase in granularity measured by side scatter (side scatter, on Y-axis) and cell size measured by forward scatter (forward scatter, on X-axis), which was in good agreement with our AO/EB staining observation. Cells treated with DOX or SWNTs showed no detectable expression of CD61 (GPIIIa) (shown in Fig. S7), whereas in K562 cells co-administered with cyclin A2 siRNA and DOX, the fraction of CD61 (GPIIIa) positive cells (approximately10%) was clearly observed (Fig. 8). For NBT reduction assay, representative microscopy images of K562 cells after various treatments were shown in Fig. S8. In cells treated with DOX or SWNTs, the percentage of NBT positive cells was very low (1%), whereas a small fraction NBT positive cells (approximately6%) was observed in K562 cells co-administered with cyclin A2 siRNA and DOX (Fig. 9). Although the fractions of cells undergoing megakaryocytic pathway (approximately10%) and monocyte-macrophage differentiation (approximately6%) were small, the difference is statistically significant compared to the control group. Considering that DOX is an erythroid differentiation-inducing agent for K562 cells [21], [42], [43], it is not surprising that only a small fraction of K562 cells with reduced cyclin A2 underwent megakaryocytic pathway and monocyte-macrophage differentiation.
###end p 33
###begin title 34
###xml 128 129 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Flow cytometric measurement of megakaryocytic specific surface antigen CD61 (GPIIIa) in K562 cells co-administered with cyclin A2 siRNA and DOX.
###end title 34
###begin p 35
Cells were transfected with siRNA by SWNTs two hours prior to the administration of 0.4 microM DOX. Sixty hours later, expressions of CD61 (GPIIIa) were evaluated by using FITC-conjugated isotype control immunoglobulin and specific anti-CD61 (GPIIIa) FITC-conjugated monoclonal antibody. The marker placed to the right of histogram designates positive events.
###end p 35
###begin title 36
###xml 36 37 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Knocking-down expression of cyclin A2 in K562 cells induced monocyte-macrophage differentiation upon administration of DOX.
###end title 36
###begin p 37
###xml 322 323 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Cells were transfected with siRNA by SWNTs two hours prior to the treatment of 0.4 microM DOX. Ninety six hours later, NBT dye reduction was used to qualitatively monitor monocyte-macrophage differentiation. Tests were done twice, counting a minimum of 300 total cells from at least three random microscope fields each. **p<0.001 vs. control untreated cells by Student's t-test.
###end p 37
###begin p 38
###xml 84 85 84 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 191 192 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 328 329 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Taken together, these results indicate that knocking down the expression of cyclin A2 suppressed DOX-induced erythroid differentiation and a small fraction of K562 cells with reduced cyclin A2 were differentiated along megakaryocytic and monocyte-macrophage pathways upon treatment with DOX. These findings suggest that cyclin A2 is an important regulator of cell differentiation.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 183 184 183 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 298 299 298 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 435 436 435 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 474 477 474 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Bui1">[6]</xref>
###xml 478 482 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Liao1">[15]</xref>
###xml 551 552 551 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 677 678 677 678 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 804 808 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wolowiec1">[13]</xref>
###xml 810 814 810 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Paterlini1">[14]</xref>
Cyclin A2 is particularly interesting among the cyclin family because it can activate two different CDKs and functions in both S phase and mitosis. In S phase, phosphorylated cyclin A2-CDK2 complexes are suggested to play an important role in the initiation of DNA replication. In mitosis, cyclin A2 may contribute to the control of cyclin B stability. Consistent with its role as a key cell cycle regulator, overexpression of cyclin A2 is associated with transformed cells [6]-[15]. However, it is difficult to determine whether elevation of cyclin A2 is a contributing factor or a mere consequence of the increased cell proliferation. In haematological malignancies, cyclin A2 is associated with proliferation rate of these disorders and can be used for molecular diagnostics as a proliferation marker [13], [14].
###end p 40
###begin p 41
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang1">[20]</xref>
###xml 652 653 652 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 766 767 766 767 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 843 844 843 844 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 997 1001 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang1">[20]</xref>
Single-walled carbon nanotubes (SWNTs) have been considered as the leading candidate for nanodevice applications ranging from gene therapy and novel drug delivery to membrane separations. We have previously showed that siRNA transfection efficiency of lipofectamine 2000 in K562 cells was low (28%) and some cells underwent apoptosis and necrosis during the process [20]. However, SWNTs could efficiently facilitate the coupling of siRNA to form siRNA:SWNTs complexes and carry siRNA into K562 cells, significantly knocking down the expression of target gene. No apparent cell toxicology was observed. Hence, in order to directly probe whether cyclin A2 participates in cell apoptosis and differentiation, we employed SWNTs as transfection vector to deliver cyclin A2 siRNA into K562 cells to specifically knock down the expression of cyclin A2 and found that carbon nanotubes vector showed no additive or synergetic effect on cell toxicology of DOX, which was consistent with our previous report [20].
###end p 41
###begin p 42
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Gewirtz1">[42]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Minotti1">[43]</xref>
###xml 595 603 <span type="species:ncbi:9606">patients</span>
DOX, a prominent member of anthracycline antibiotics, has been extensively used for treatment of solid tumors and leukemia. It exerts its cytotoxic activity against cancer cells mainly by intercalation into DNA, inhibition of topoisomerase II and helicase activity, leading to cell-cycle arrest at the G2/M phase and apoptosis [42]. In clinical applications, doses of DOX are strictly limited by its cardiotoxicity [43]. It should be noted that the dose of DOX administrated here (0.4 microM) is pharmacological relevant compared to the initial or steady-state plasma concentrations observed in patients after standard bolus infusions (5 microM and 25-250 nM, respectively).
###end p 42
###begin p 43
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Zuryn1">[22]</xref>
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang2">[28]</xref>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 198 199 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 297 301 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Hoang1">[24]</xref>
###xml 378 379 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 443 444 443 444 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 563 564 563 564 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 657 658 657 658 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Meikrantz1">[25]</xref>
###xml 752 756 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Meikrantz2">[26]</xref>
###xml 780 786 780 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 867 868 867 868 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 949 950 949 950 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 989 993 989 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Hiromura1">[27]</xref>
###xml 1054 1055 1054 1055 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1181 1182 1181 1182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1295 1296 1295 1296 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1363 1364 1363 1364 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 149 152 <span type="species:ncbi:10116">rat</span>
###xml 328 331 <span type="species:ncbi:10116">rat</span>
###xml 729 734 <span type="species:ncbi:9606">human</span>
It has been reported that there is a link between cyclin A2 and apoptosis [22]-[28]. Hoang et al. showed that in c-myc overexpressing serum deprived rat 1A fibroblasts undergoing apoptosis, cyclin A2 mRNA expression was increased, in contrast to the invariant expression for cyclin B, C, D1 and E [24]. Moreover, serum-deprived rat 1A fibroblast stably transfected with cyclin A2 exhibited increased apoptosis following stimulation of cyclin A2 expression. Meikrantz et al. reported that induction of apoptosis was uniformly associated with activation of cyclin A2-dependent kinases but not associated with cyclins E or B, and overexpression of the cyclin A2 could circumvent the anti-apoptosis activity of the oncogene BCL-2 in human Hela cells [25], [26]. Furthermore, Hiromura et al. indicated that apoptosis was associated with an increase in cytoplasmic cyclin A2-CDK2 activity following UV irradiation, under these conditions, nuclear cyclin A2-Cdk2 activity decreased significantly [27]. Our results showed knocking down the expression of cyclin A2 in K562 cells significantly suppressed the apoptosis induced by DOX and a positive correlation between the levels of cyclin A2 and apoptosis was observed. The findings also indicate that the cytoplasmic subcellular distribution of cyclin A2 correlates with its pro-apoptotic role. We speculate that cyclin A2 associated kinases are involved in DOX-induced apoptotic cell death pathways in K562 cells, although the exact downstream mechanisms are not known.
###end p 43
###begin p 44
###xml 66 67 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 143 144 143 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 217 218 217 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang1">[20]</xref>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Karlsson1">[44]</xref>
###xml 449 453 449 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Stl1">[45]</xref>
###xml 658 662 658 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Gewirtz1">[42]</xref>
###xml 734 735 734 735 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
We have demonstrated that SWNTs could effectively deliver cyclin A2 siRNA into K562 cells, significantly suppressing the expression of cyclin A2 with specificity and cell proliferation, and cells with reduced cyclin A2 showed a decrease in the percentage of cells in S phase [20]. Several studies have indicated that cancer cells with a high S-phase fraction/high proliferative activity are more sensitive to apoptosis induced by chemotherapy [44], [45]. As for DOX, it is active throughout the cell cycle, but the effect is most pronounced for cells in S phase-G2 phase, especially in S phase, where it interferes with the DNA replication and transcription [42]. Therefore, it was not surprising that K562 cells with reduced cyclin A2 showed a marked decrease in DOX susceptibility.
###end p 44
###begin p 45
###xml 322 323 322 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 380 384 380 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Chao1">[10]</xref>
###xml 385 389 385 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wolowiec1">[13]</xref>
###xml 476 477 476 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 556 557 556 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 588 589 588 589 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 652 653 652 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 689 693 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Kawashima1">[46]</xref>
###xml 694 698 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-RodriguezPinilla1">[48]</xref>
###xml 758 759 758 759 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 848 849 848 849 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 906 912 906 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 955 956 955 956 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1061 1062 1061 1062 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1142 1146 1142 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Yam1">[49]</xref>
###xml 1222 1223 1222 1223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1342 1343 1342 1343 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1549 1550 1549 1550 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1559 1560 1559 1560 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 189 196 <span type="species:ncbi:9606">patient</span>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
###xml 763 768 <span type="species:ncbi:9606">human</span>
###xml 1233 1241 <span type="species:ncbi:9606">patients</span>
###xml 1306 1314 <span type="species:ncbi:9606">Patients</span>
Most of chemotherapeutic agents show significant side effects and not all patients benefit from aggressive chemotherapy. Therefore, searching for tumor biological factors which can predict patient prognosis and chemotherapy response would be of most importance. Several studies have indicated that a high level of cyclin A2 expression may be a marker of poor prognosis in cancers [10]-[13]. Besides, previous studies have shown that cancer patients with high level of cyclin A2 had better chemotherapy response and survival than those with reduced cyclin A2 and low expression of cyclin A2, indicating that the patients with high expression of cyclin A2 are more suitable for chemotherapy [46]-[48]. Our results demonstrate the pro-apoptotic role of cyclin A2 in human myeloid leukemia K562 cells, and indicate that cells with low level of cyclin A2 were more resistant to chemotherapeutic agent DOX. Poon et al. have suggested that a decrease of cyclin A2, rather than increase, promotes tumorigenesis, and once the tumor has developed, high levels of cyclin A2 simply reflect a high proliferation rate, which can explain this inconsistency [49]. Hence, despite its association with transformed cells, evaluating cyclin A2 level in patients will be an important prognostic marker for use of chemotherapy. Patients with high level of cyclin A2 may be more responsive to anticancer drugs through the induction of apoptotic cell death. Moreover, it should be cautious to combine doxorubicin chemotherapy with any small molecule drug targeting cyclin A2/cyclin A2 associated kinases since it can enhance potential drug resistance.
###end p 45
###begin p 46
###xml 73 74 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-HoriguchiYamada1">[29]</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Rieber1">[33]</xref>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 199 200 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 262 266 262 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Ito1">[31]</xref>
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 430 431 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 492 493 492 493 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Kiyokawa1">[30]</xref>
###xml 592 597 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 633 634 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 817 821 817 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Yoshizumi1">[32]</xref>
###xml 840 845 840 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 892 893 892 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 981 985 981 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Rieber1">[33]</xref>
###xml 1055 1056 1055 1056 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1185 1186 1185 1186 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1466 1467 1466 1467 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1680 1681 1680 1681 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1823 1824 1823 1824 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 323 329 <span type="species:ncbi:10090">murine</span>
###xml 749 754 <span type="species:ncbi:9606">human</span>
###xml 759 762 <span type="species:ncbi:10116">rat</span>
In several systems, it has been reported that down-regulation of cyclin A2 and its associated CDK 2 activity are important for successful differentiation [29]-[33]. Ito et al. have suggested cyclin A2 overexpression is directly related with poor differentiation [31]. Kiyokawa et al. have indicated that differentiation of murine erythroleukemia cells induced by hexamethylene is accompanied by a decrease in the level of cyclin A2 and CDK2 proteins and the persistent suppression of cyclin A2 expression may play a role in HMBA-induced commitment to terminal differentiation [30]. Yoshizumi et al. showed down-regulation of cyclin A2 gene expression in vivo at both the RNA and protein levels appears to be important in the permanent withdrawal of human and rat cardiomyocytes from the cell cycle during development [32]. Moreover, Rieber et al. demonstrated that the interaction of cyclin A2 with E2F is the target for tyrosine induction of B16 melanoma terminal differentiation [33]. In this work, we found that knocking down the expression of cyclin A2 in K562 cells significantly suppressed DOX-induced erythroid differentiation and a small fraction of cells with reduced cyclin A2 were differentiated along megakaryocytic and monocyte-macrophage pathways upon treatment with DOX. To the best of our knowledge, this is the first report that knocking down expression of one gene can switch K562 cells differentiation pathways. The results suggested that cyclin A2 is directly involved in the checkpoint of cell differentiation pathways and is a key regulator of this process, although the detail downstream mechanisms are not known. For cancer cells with low level of cyclin A2, which are less responsive to chemotherapeutic agents, induction of differentiation might be an alternative strategy. Combination of cyclin A2 siRNA and DOX may provide a novel option of such therapeutic strategy.
###end p 46
###begin p 47
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 343 344 343 344 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 370 371 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 451 452 451 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 208 213 <span type="species:ncbi:9606">human</span>
In conclusion, knocking down the expression of cyclin A2 by siRNA delivered by SWNTs suppresses apoptosis and erythroid differentiation, and promotes megakaryocytic and monocyte-macrophage differentiation in human chronic myelogenous leukaemia K562 cells upon administration with DOX. The results demonstrate the pro-apoptotic role of cyclin A2 and suggest that cyclin A2 is a key regulator of cell differentiation, supporting the notion that cyclin A2 is an important regulator for cell cycle as well as for cell apoptosis and differentiation.
###end p 47
###begin title 48
Materials and Methods
###end title 48
###begin title 49

###end title 49
###begin title 50
Ethics statement
###end title 50
###begin p 51
###xml 41 45 41 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang1">[20]</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human erythroleukemic cell line K562 [20] was used in this study.
###end p 51
###begin title 52
Chemicals
###end title 52
###begin p 53
Doxorubicin (DOX), Acridine Orange (AO), Ethidium Bromide (EB), Methylthiazolyldiphenyl-tetrazolium bromide (MTT), DAPI, Nitro blue tetrazolium (NBT), benzidine and SWNTs (phi = 1.1 nm, purity>90%) were purchased from Sigma-Adrich (St. Louis, MO, USA). Annexin V apoptosis detection kit was obtained from Keygentec (Nanjing, China). The dye mix for the EB/AO staining was 100 microg/mL acridine orange and 100 microg/mL ethidium bromide in phosphate buffered saline (PBS).
###end p 53
###begin title 54
Cell culture
###end title 54
###begin p 55
###xml 41 45 41 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang1">[20]</xref>
###xml 193 194 187 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 135 139 <span type="species:ncbi:9913">calf</span>
The human erythroleukemic cell line K562 [20] was grown in Iscove's modified Dulbecco's medium (Gibco BRL) supplemented with 10% fetal calf serum in a humidified 37degreesC incubator with 5% CO2. Cells were passed three times per week. DNA fluorochrome staining (DAPI or Hoechst 33258) is used as our routine mycoplasma detection and the cells used for experiments are free of contamination. Exponentially growing cells were used for all experiments described below. Cell viability was determined by trypan blue exclusion in a haemocytometer chamber.
###end p 55
###begin title 56
Transfection
###end title 56
###begin p 57
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 148 176 148 176 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCAUUGGUC CCUCUUGAUUTT-3&#8242;</named-content>
###xml 256 277 256 277 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">UUCUCCGAACGUGUCACGUTT</named-content>
###xml 391 395 391 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Wang1">[20]</xref>
###xml 405 406 405 406 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 435 442 435 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f-SWNTs</sub>
###xml 445 450 445 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siRNA</sub>
The siRNA oligonucleotides were synthesized by Genepharma Corporation (Shanghai, China). The sequence used for targeting silencing of cyclin A2 was 5'-CCAUUGGUC CCUCUUGAUUTT-3'. The nonsilencing control siRNA is an irrelevant siRNA with random nucleotides UUCUCCGAACGUGUCACGUTT. Functionalized single wall nanotubes (f-SWNTs) were prepared according to method described in our previous work [20]. Cyclin A2 siRNA: f-SWNTs complexes (w f-SWNTs/w siRNA = 40) were added at 25 n mol/L (siRNA concentration) to culture of cells.
###end p 57
###begin title 58
Reverse transcriptase-polymerase chain reaction (RT-PCR)
###end title 58
###begin p 59
###xml 143 144 143 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 150 176 150 176 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TCCATGTCAGTGCTGAGAGGA (5&#8242;)</named-content>
###xml 178 203 178 203 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GAAGGTCCATGAGACAAGGC (3&#8242;)</named-content>
###xml 485 510 467 492 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">ACCTGACCTGCCGTCTAGAA (5&#8242;)</named-content>
###xml 512 537 494 519 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TCCACCACCCTGTTGCTGTA (3&#8242;)</named-content>
###xml 637 638 619 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 756 758 734 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
Total RNA was extracted using Trizol reagent (Invitrogen) according to the manufacturer's instructions. The primers and conditions for cyclin A2 were TCCATGTCAGTGCTGAGAGGA (5'), GAAGGTCCATGAGACAAGGC (3'); 94degreesC for 30 seconds , 60degreesC for 30 seconds, 72degreesC for 1 minute for 25 cycles. Three introns are present in this pair of primer so that any contaminating genomic DNA would not be amplified. Primers used for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were ACCTGACCTGCCGTCTAGAA (5'), TCCACCACCCTGTTGCTGTA (3'). Two sets of primers were used for each sample, including primers specific for the gene of cyclin A2 and primers for GAPDH as an internal control. All PCR products were visualized on 1.5% agarose gel with 0.5 microg mL-1 EB.
###end p 59
###begin title 60
Western blotting
###end title 60
###begin p 61
###xml 856 857 837 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1316 1320 1297 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006665-Yong1">[50]</xref>
###xml 825 831 <span type="species:ncbi:9986">rabbit</span>
###xml 1080 1084 <span type="species:ncbi:9925">goat</span>
###xml 1090 1096 <span type="species:ncbi:9986">rabbit</span>
###xml 1115 1126 <span type="species:ncbi:3704">horseradish</span>
For Western blot analysis, cells were lysed in radio-immunoprecipitation assay (RIPA) buffer (150 mmol/L NaCl, 50 mmol/L Tris-HCl, 0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS, pH 7.6) containing protease inhibitors for protein extraction. Protein concentrations were determined using the Bradford assay. 20 microg cell samples were denatured by addition of 2x reducing sample buffer (100 mmol/L Tris, 4% SDS, 25% glycerol, 10% beta-mercaptoethanol, 0.01% bromphenol blue, pH 6.8), incubated for 10 minutes at 95degreesC, and separated on a 12% SDS-PAGE. The proteins were electroblotted to PVDF membrane. After blocking with Tris-buffered saline containing 0.05% Tween 20 (TTBS) and 2% BSA, the membranes were incubated overnight at 4degreesC with appropriate primary antibody diluted in TTBS. Working dilutions were: 1/500 rabbit polyclonal anti-cyclin A2 primary antibody (Lab Vision Corporation, CA, USA); 1/400 anti-GAPDH primary antibody (Santa Cruz, CA, USA). The membranes were washed three times in TTBS for 5 min each and then incubated for 1 h at room temperature with goat anti-rabbit IgG conjugated to horseradish peroxidase (Jackson Immunoresearch, Stratech, UK). After extensive washing in TTBS, the protein-antibody complexes were visualized by CN/DAB substrate according to method described by Yong [50]. Images were photographed using a UVP gel documentation system (Ultraviolet Products, Upland, CA, USA).
###end p 61
###begin title 62
MTT assay
###end title 62
###begin p 63
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
K562 cells were plated in 96-well culture plate at a concentration of 0.5x104 cells/well, and were transfected with cyclin A2 siRNA or not by SWNTs. Two hours later, the cells were treated with various concentrations of DOX while the blank control wells were added medium without drug. Cells were then cultured for another 24 hours and 20 microL MTT (5 mg/mL) was added in each well, followed by additional four hour incubation. The supernatants were then discarded carefully and 150 microL dimethylsulphoxide was added and shaken vigorously to dissolve the purple precipitation formation. Optical density (OD) of each well was tested using Bio-Rad model-680 microplate reader with a wavelength of 490 nm.
###end p 63
###begin title 64
Cell fluorescence staining
###end title 64
###begin p 65
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 140 141 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Cells were collected by centrifugation at 200xg for 5 minutes, and then washed twice with PBS. Cell concentration was adjusted as 2x106-5x106 cells/mL. 1 microL EB/AO dye mix was added in 10 microL cell suspension, followed by 10 minutes of incubation in dark. Stained cells suspension were placed on a clean microscope slide and covered with a cover-slip. Cells were viewed and counted using an Olympus BX-51 optical system microscope (Tokyo, Japan) at 400x magnification with a blue filter. Pictures were taken with an Olympus digital camera. We note that the definition is sharper by eye through the microscope than in the photo. Tests were done in triplicate, counting a minimum of 300 total cells from at least three random microscope fields each.
###end p 65
###begin title 66
Indirect immunofluorescence detection
###end title 66
###begin p 67
###xml 235 236 223 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 207 211 <span type="species:ncbi:9925">goat</span>
###xml 247 253 <span type="species:ncbi:9986">rabbit</span>
###xml 317 321 <span type="species:ncbi:9925">Goat</span>
###xml 327 333 <span type="species:ncbi:9986">rabbit</span>
Cells were harvested, washed three times with PBS, fixed with 4% paraformaldehyde in PBS for 30 min at 4degreesC and permeabilized with 0.5% Triton X-100 in PBS for 5 min at 4degreesC. After blocking in 10% goat serum, primary cyclin A2 antibody (rabbit, polyclonal; Lab Vision Corporation, CA) was diluted to 1:400. Goat anti-rabbit FITC-conjugated secondary antibody (Jackson Immunoresearch, Stratech, UK) was used at a 1:200 dilution. If necessary, DAPI was used to visualize cell nuclei. Cells were observed and photographed by fluorescence microscopy with oil immersion objective and appropriate filters.
###end p 67
###begin title 68
Benzidine Staining
###end title 68
###begin p 69
###xml 305 306 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 307 308 299 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Erythroid differentiation was scored by the benzidine staining method for the determination of the percentage of hemoglobin-positive K562 cells induced by low concentration DOX. Briefly, cells were washed twice and then resuspended in 20 microL PBS. 10 microL of benzidine solution (0.2% benzidine, 0.6% H2O2, 0.5 M acetic acid) was added and incubated for 20 min at room temperature in the dark. Benzidine-positive cells (blue-black staining) were quantitated by light microscopy. At least 300 cells were counted in triplicate for each condition.
###end p 69
###begin title 70
Flow cytometry analysis
###end title 70
###begin p 71
###xml 590 591 586 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 751 752 747 748 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 306 311 <span type="species:ncbi:10090">mouse</span>
###xml 567 571 <span type="species:ncbi:9913">calf</span>
Expression of GPIIIa is considered the most selective marker of the megakaryocyte lineage since it is not expressed on cells of other hematopoietic lineages from normal human bone marrow. Hence, staining of cells for surface CD61 (GPIIIa) was used to evaluate megakaryocytic differentiation. It employed a mouse monoclonal antibody fluorescein isothiocyanate (FITC)-conjugated anti-CD61 (eBioscience) or isotype-matched immunoglobulin (IgG1-FITC, eBioscience) at a concentration of 0.6 microg/mL. Cells were harvested, washed, resuspended in PBS containing 10% fetus calf serum and 0.1% NaN3 and incubated for 30 min on ice with antibodies in the dark. After washing three times, cells were resuspended in PBS containing 0.5% formaldehyde and 0.1% NaN3, and then analyzed on a FACS Arial cytometer (Becton-Dickinson, San Diego, CA, USA). Viable cells were gated using forward and side scatter characteristics. Fluorescence intensity data were acquired using the BD FACSDIVAtrade mark software.
###end p 71
###begin title 72
NBT reduction assay
###end title 72
###begin p 73
NBT dye reduction was used to qualitatively monitor monocyte-macrophage differentiation. Briefly, cells were collected, washed with PBS and resuspended in IMDM medium without serum. Cells suspension were mixed with an equal volume of 0.1% NBT dissolved in PBS and incubated at 37degreesC for 40 min. NBT was reduced to insoluble formazan because of the intracellular oxygen radical release in the cells differentiated to monocytes-macrophages. The percentage of cells containing intracellular reduced blue-black formazan was determined by light microscopy. At least 300 cells per preparation were observed.
###end p 73
###begin title 74
Statistical analysis
###end title 74
###begin p 75
###xml 167 168 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Data are expressed as mean+/-s.d. and analysis of variance was carried out using Student's t test with Origin 7.5 (OriginLab Corporation, Northampton, MA, USA), where p<0.05 was considered significant.
###end p 75
###begin title 76
Supporting Information
###end title 76
###begin p 77
Knocking-down the expression of cyclin A2 in K562 cells significantly suppressed growth inhibition and apoptosis induced by DOX. Cells were plated in 6-well plate at a density of 0.8x105 cells/mL and transfected with cyclin A2 siRNA (A, B) or not (C, D) by SWNTs two hours prior to the administration of 0.4 microM DOX. 96 hours later, cells were viewed using an inverted microscope with objectivesx10 (A, C) and x40 (B, D). Pictures were taken with an Olympus digital camera. Shown here are the representative images of three independent experiments.
###end p 77
###begin p 78
(0.72 MB TIF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
Chemical interaction of DOX with MTT assay. The assay was performed as follows: 200 microL of medium containing DOX at different concentrations was placed in a 96-well plate; 20 microL of MTT solution (5 mg/mL) was added to each well; After incubation for 4 h at 37degreesC, 150 microL of DMSO was added to each well and absorbance at 490 nm was measured in a Bio-Rad model-680 microplate reader. DOX-free complete medium was used as control and was treated in the same way as the DOX-containing media. Variation (%) = (absorbance of DOX containing medium - absorbance of control)/absorbance of controlx100.
###end p 80
###begin p 81
(3.08 MB TIF)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
Annexin V-PI double staining of cells after various treatments. Upper left, untreated control; upper right, cells treated with transfection vector SWNTs; lower left, cells treated with 0.4 microM DOX for 32 h; lower right, two hours after cyclin A2 siRNA transfection, cells were then administered with 0.4 microM DOX for additional 32 h.
###end p 83
###begin p 84
(0.24 MB TIF)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
Indirect immunofluorescence detection of cyclin A2 in control K562 cells. DAPI was used to visualize cell nuclei. Cells were viewed using an Olympus BX-51 optical system microscope (Tokyo, Japan) with oil lens and appropriate filters. Representative stained fields are shown: (A), DAPI staining (blue); (B), immunofluorescence detection of cyclin A2 (FITC, green); (C) merged image. As indicated, cyclin A2 was located at the nucleus of K562 cells without DOX treatment.
###end p 86
###begin p 87
(0.43 MB TIF)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin p 89
###xml 306 327 302 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
Representative microscopy images of the benzidine staining of K562 cells after various treatments. Cells were transfected with cyclin A2 siRNA or not two hours prior to the addition of 0.4 microM DOX. Forty hours later, erythroid differentiation was scored by the benzidine staining method as described in Materials and Methods section. Cells were viewed and counted using an Olympus BX-51 optical system microscope (Tokyo, Japan) at 200x magnification. Four independent tests were performed. Pictures were taken with an Olympus digital camera.
###end p 89
###begin p 90
(0.65 MB TIF)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin p 92
Morphological changes of K562 cells after various treatments. Cells were transfected with cyclin A2 siRNA or not two hours prior to the administration of 0.4 microM DOX. Cells were then cultured for another 32 hours. Flow cytometry was used to show changes in size (forward scatter, on X-axis) and granularity (side scatter, on Y-axis). No significant morphological changes of K562 cells were observed upon RNAi mediated by SWNTs compared to the control. Cells administered with DOX underwent G2/M arrest and changes in granularity and cell size were clearly observed. Although knocking-down the expression of cyclin A2 by RNAi significantly inhibited growth suppression and apoptosis induced by DOX, cells co-administered with siRNA targeting for cyclin A2 and DOX showed similar increases in cell size and granularity compared to those treated with DOX alone.
###end p 92
###begin p 93
(2.11 MB TIF)
###end p 93
###begin p 94
Click here for additional data file.
###end p 94
###begin p 95
Flow cytometric measurement of megakaryocytic specific surface antigen CD61 (GPIIIa) in K562 cells. Cells were incubated with 0.4 microM DOX (A, B) or SWNTs (C, D) for 60 h. Expressions of CD61 (GPIIIa) were evaluated by using FITC-conjugated isotype control immunoglobulin (A, C) and specific anti-CD61 (GPIIIa) FITC-conjugated monoclonal antibody (B, D). The marker placed to the right of histogram designates positive events. K562 cells administrated with low concentration of DOX or SWNTs did not undergo apparent megakaryocytic differentiation.
###end p 95
###begin p 96
(1.96 MB TIF)
###end p 96
###begin p 97
Click here for additional data file.
###end p 97
###begin p 98
Representative microscopy images of the NBT reduction assay of K562 cells after various treatments. Cells were transfected with cyclin A2 siRNA or not two hours prior to the addition of 0.4 microM DOX. Ninety six hours later, NBT dye reduction was used to qualitatively monitor monocyte-macrophage differentiation. Cells were viewed and counted using an Olympus BX-51 optical system microscope (Tokyo, Japan) at 200x magnification. Two independent tests were performed. Pictures were taken with an Olympus digital camera.
###end p 98
###begin p 99
(0.34 MB TIF)
###end p 99
###begin p 100
Click here for additional data file.
###end p 100
###begin p 101
We thank Yong Chen (College of Life Science, Jilin University) and Professor Yongchen Zheng (Central Laboratory of the 2nd Hospital, Jilin University) for their technical assistance.
###end p 101
###begin title 102
References
###end title 102
###begin article-title 103
Cell cycle control and cancer.
###end article-title 103
###begin article-title 104
###xml 27 37 <span type="species:ncbi:7227">Drosophila</span>
Expression and function of Drosophila cyclin A during embryonic cell cycle progression.
###end article-title 104
###begin article-title 105
Cyclin A is required for the onset of DNA replication in mammalian fibroblasts.
###end article-title 105
###begin article-title 106
###xml 42 47 <span type="species:ncbi:9606">human</span>
Cyclin A is required at two points in the human cell cycle.
###end article-title 106
###begin article-title 107
Localization of cyclin A at the sites of cellular DNA replication.
###end article-title 107
###begin article-title 108
Cyclin A expression in normal and transformed alveolar epithelial cells.
###end article-title 108
###begin article-title 109
Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness.
###end article-title 109
###begin article-title 110
Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms.
###end article-title 110
###begin article-title 111
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
###end article-title 111
###begin article-title 112
###xml 78 83 <span type="species:ncbi:9606">human</span>
Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma.
###end article-title 112
###begin article-title 113
Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer.
###end article-title 113
###begin article-title 114
Prognostic significance of cyclin A in gastric cancer.
###end article-title 114
###begin article-title 115
CDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-Hodgkin's lymphomas.
###end article-title 115
###begin article-title 116
###xml 23 28 <span type="species:ncbi:9606">human</span>
Cyclin A expression in human hematological malignancies: a new marker of cell proliferation.
###end article-title 116
###begin article-title 117
Elevated levels and distinct patterns of expression of A-type cyclins and their associated cyclin-dependent kinases in male germ cell tumors.
###end article-title 117
###begin article-title 118
CDK inhibitors in cancer therapy: what is next?
###end article-title 118
###begin article-title 119
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.
###end article-title 119
###begin article-title 120
###xml 62 68 <span type="species:ncbi:10090">murine</span>
Delayed early embryonic lethality following disruption of the murine cyclin A2 gene.
###end article-title 120
###begin article-title 121
Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo.
###end article-title 121
###begin article-title 122
Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells.
###end article-title 122
###begin article-title 123
###xml 40 45 <span type="species:ncbi:9606">human</span>
Effects of anthracycline derivatives on human leukemia K562 cell growth and differentiation.
###end article-title 123
###begin article-title 124
###xml 26 31 <span type="species:ncbi:9606">human</span>
Expression of cyclin A in human leukemia cell line HL-60 following treatment with doxorubicin and etoposide: the potential involvement of cyclin A in apoptosis.
###end article-title 124
###begin article-title 125
The effect of doxorubicin on the expression of cyclin A in K-562 leukemia cell line.
###end article-title 125
###begin article-title 126
Participation of cyclin A in Myc-induced apoptosis.
###end article-title 126
###begin article-title 127
Suppression of apoptosis by dominant negative mutants of cyclin- dependent protein kinases.
###end article-title 127
###begin article-title 128
Activation of cyclin A-dependent protein kinases during apoptosis.
###end article-title 128
###begin article-title 129
The subcellular localization of cyclin dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation.
###end article-title 129
###begin article-title 130
Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen.
###end article-title 130
###begin article-title 131
Changes of G1 cyclins, cdk2, and cyclin A during the differentiation of HL60 cells induced by TPA.
###end article-title 131
###begin article-title 132
Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells.
###end article-title 132
###begin article-title 133
Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma.
###end article-title 133
###begin article-title 134
###xml 104 109 <span type="species:ncbi:9606">human</span>
###xml 114 117 <span type="species:ncbi:10116">rat</span>
Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts.
###end article-title 134
###begin article-title 135
Cyclin-dependent kinase 2 and cyclin A interaction with E2F are targets for tyrosine induction of B16 melanoma terminal differentiation.
###end article-title 135
###begin article-title 136
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy.
###end article-title 136
###begin article-title 137
###xml 20 25 <span type="species:ncbi:9606">human</span>
siRNA delivery into human T cells and primary cells with carbon-nanotube transporters.
###end article-title 137
###begin article-title 138
Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway.
###end article-title 138
###begin article-title 139
Carbon nanotubes selective destabilization of duplex and triplex DNA and inducing B-A transition in solution.
###end article-title 139
###begin article-title 140
###xml 68 73 <span type="species:ncbi:9606">human</span>
Carboxyl-modified single-walled carbon nanotubes selectively induce human telomeric i-motif formation.
###end article-title 140
###begin article-title 141
###xml 42 47 <span type="species:ncbi:9606">human</span>
Single-walled carbon nanotubes binding to human telomeric i-motif DNA: significant acceleration of S1 nuclease cleavage rate.
###end article-title 141
###begin article-title 142
Self-assembly of single-stranded RNA on carbon nanotube: polyadenylic acid to form a duplex structure.
###end article-title 142
###begin article-title 143
###xml 42 47 <span type="species:ncbi:9606">Human</span>
Single-Walled Carbon Nanotubes Binding to Human Telomeric i-Motif DNA Under Molecular-Crowding Conditions: More Water Molecules Released.
###end article-title 143
###begin article-title 144
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
###end article-title 144
###begin article-title 145
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
###end article-title 145
###begin article-title 146
Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma.
###end article-title 146
###begin article-title 147
S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.
###end article-title 147
###begin article-title 148
###xml 44 49 <span type="species:ncbi:9606">human</span>
Cyclin A correlates with the sensitivity of human cancer cells to cytotoxic effects of 5-FU.
###end article-title 148
###begin article-title 149
###xml 114 122 <span type="species:ncbi:9606">patients</span>
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.
###end article-title 149
###begin article-title 150
Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
###end article-title 150
###begin article-title 151
Cyclin A in cell cycle control and cancer.
###end article-title 151
###begin article-title 152
An improved method for the detection of peroxidase-conjugated antibodies on immunoblots.
###end article-title 152
###begin p 153
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 153
###begin p 154
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by NSFC (20831003, 90813001, 20833006) and funds from the Chinese Academy of Sciences and Jilin Province. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 154

